Event Brief
Experimental daraxonrasib pill extends survival in pancreatic cancer
Filed: May 31, 2026 at 11:02 AM ET
Summary: A trial found daraxonrasib nearly doubled survival for advanced pancreatic cancer patients with fewer severe side effects.
WHO: Dr. Zev Wainberg, University of California, Los Angeles
WHAT: Researchers reported that the experimental pill daraxonrasib nearly doubled survival time in a randomized study of advanced pancreatic cancer patients.
WHEN: May 31, 2026 at 9:00 AM ET
WHERE: USA
WHY: The drug blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
📋 This story has 3 earlier reports
🔍 9 sources analyzed
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →